| 6.38 0.1 (1.59%) | 06-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.65  |
1-year : | 11.2 |
| Resists | First : | 8.26 |
Second : | 9.59 |
| Pivot price | 7.54 |
|||
| Supports | First : | 6.11 |
Second : | 5.08 |
| MAs | MA(5) : | 6.57 |
MA(20) : | 7.8 |
| MA(100) : | 12.17 |
MA(250) : | 16.99 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 8 |
D(3) : | 6.3 |
| RSI | RSI(14): 29.4 |
|||
| 52-week | High : | 33.68 | Low : | 6.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ UPB ] has closed above bottom band by 12.8%. Bollinger Bands are 53.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 68 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.81 - 6.85 | 6.85 - 6.88 |
| Low: | 6.14 - 6.19 | 6.19 - 6.23 |
| Close: | 6.21 - 6.28 | 6.28 - 6.34 |
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Wed, 10 Jun 2026
UPB: Quarterly dosing with verekitug shows best-in-class efficacy in asthma and CRSwNP, phase III next year - TradingView
Mon, 08 Jun 2026
Upstream Bio to Showcase Additional Efficacy Data from the - GlobeNewswire
Mon, 08 Jun 2026
Nasal polyp drug Verekitug Phase 2 data to be aired at EAACI 2026 - Stock Titan
Sun, 07 Jun 2026
Why Did UPB Stock Plunge 40% Today? - Stocktwits
Fri, 05 Jun 2026
UPB News | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Wed, 03 Jun 2026
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 3.497e+007 (%) |
| Held by Institutions | 14.8 (%) |
| Shares Short | 3,020 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7177e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 218 % |
| Return on Equity (ttm) | -27.8 % |
| Qtrly Rev. Growth | 3.32e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -140 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 3.4e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|